Please use this identifier to cite or link to this item:
|Title:||MiR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme||Authors:||Yin, D.
Phillip Koeffler, H.
|Issue Date:||28-Feb-2013||Citation:||Yin, D., Ogawa, S., Kawamata, N., Leiter, A., Ham, M., Li, D., Doan, N.B., Said, J.W., Black, K.L., Phillip Koeffler, H. (2013-02-28). MiR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. Oncogene 32 (9) : 1155-1163. ScholarBank@NUS Repository. https://doi.org/10.1038/onc.2012.132||Abstract:||Chromosome 1p36.23 is frequently deleted in glioblastoma multiforme (GBM). miR-34a localizes in this region. Our experiments found that miR-34a was often deleted and epidermal growth factor receptor (EGFR) was frequently amplified in genomic DNA of 55 GBMs using single-nucleotide polymorphism DNA microarray. Notably, we found that the mean survival time was significantly shortened for patients whose GBMs had both EGFR amplification and miR-34a deletion. Expression of miR-34a was significantly lower in GBM samples compared with normal brain tissue. Forced expression of miR-34a in GBM cells decreased their ability to migrate and profoundly decreased their levels of cyclin-A1, -B1, -D1, and -D3, as well as cyclin-dependent kinase and increased expression of cyclin kinase inhibitor proteins (p21, p27). Also, human GBM cells (U251) stable overexpressing mir-34a formed smaller tumors when growing as xenografts in immunodeficient mice compared with wild-type U251 GBM cells. Furthermore, the protein expression of EGFR decreased in the cells with forced overexpression of miR-34a. Additional studies showed that mir-34a targeted Yin Yang-1 (YY1) and YY1 is a transcription factor that can stimulate the expression of EGFR. Thus, our data suggest that miR-34a acts as a tumor suppressor by inhibiting growth of GBM cells in vitro and in vivo associated with moderating the expression of cell-cycle proteins and EGFR. Moreover, we discovered for the first time that both deletion of miR-34a and amplification of EGFR were associated with significantly decreased overall survival of GBM patients. © 2013 Macmillan Publishers Limited All rights reserved.||Source Title:||Oncogene||URI:||http://scholarbank.nus.edu.sg/handle/10635/126830||ISSN:||09509232||DOI:||10.1038/onc.2012.132|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on May 25, 2022
WEB OF SCIENCETM
checked on May 25, 2022
checked on May 12, 2022
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.